

# Geoff S Higgins

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8652006/publications.pdf>

Version: 2024-02-01

42  
papers

2,564  
citations

361045

20  
h-index

288905

40  
g-index

43  
all docs

43  
docs citations

43  
times ranked

4412  
citing authors

#	ARTICLE	IF	CITATIONS
1	Radiation-induced prodrug activation: extending combined modality therapy for some solid tumours. <i>British Journal of Cancer</i> , 2022, 126, 1241-1243.	2.9	2
2	Elucidating the role of transiently hypoxic tumour cells on radiation resistance. <i>British Journal of Cancer</i> , 2022, 126, 971-972.	2.9	0
3	Automated 96-well format high throughput colony formation assay for siRNA library screen. <i>STAR Protocols</i> , 2022, 3, 101355.	0.5	0
4	Targeting TOPK sensitises tumour cells to radiation-induced damage by enhancing replication stress. <i>Cell Death and Differentiation</i> , 2021, 28, 1333-1346.	5.0	13
5	Mitochondrial Inhibitor Atovaquone Increases Tumor Oxygenation and Inhibits Hypoxic Gene Expression in Patients with Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2459-2469.	3.2	40
6	Po1 $\beta$ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance. <i>Nature Communications</i> , 2021, 12, 3636.	5.8	159
7	Associations between cardiac irradiation and survival in patients with non-small cell lung cancer: Validation and new discoveries in an independent dataset. <i>Radiotherapy and Oncology</i> , 2021, 165, 119-125.	0.3	5
8	The protease SPRTN and SUMOylation coordinate DNA-protein crosslink repair to prevent genome instability. <i>Cell Reports</i> , 2021, 37, 110080.	2.9	22
9	Investigation of atovaquone-induced spatial changes in tumour hypoxia assessed by hypoxia PET/CT in non-small cell lung cancer patients. <i>EJNMMI Research</i> , 2021, 11, 130.	1.1	9
10	Targeting Tumor Hypoxia. <i>Cancer Drug Discovery and Development</i> , 2020, , 265-299.	0.2	1
11	The anti-malarial drug atovaquone potentiates platinum-mediated cancer cell death by increasing oxidative stress. <i>Cell Death Discovery</i> , 2020, 6, 110.	2.0	11
12	External Beam Radiation Therapy and Enadenotucirev: Inhibition of the DDR and Mechanisms of Radiation-Mediated Virus Increase. <i>Cancers</i> , 2020, 12, 798.	1.7	11
13	Targeting tumour hypoxia: shifting focus from oxygen supply to demand. <i>British Journal of Radiology</i> , 2019, 92, 20170843.	1.0	12
14	Reply to "The use of buparlisib as a radiosensitiser: What about toxicity?". <i>European Journal of Cancer</i> , 2019, 119, 196-197.	1.3	0
15	Tumor pH and Protein Concentration Contribute to the Signal of Amide Proton Transfer Magnetic Resonance Imaging. <i>Cancer Research</i> , 2019, 79, 1343-1352.	0.4	52
16	Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma. <i>European Journal of Cancer</i> , 2019, 113, 87-95.	1.3	35
17	[18F]FE-OTS964: a Small Molecule Targeting TOPK for In Vivo PET Imaging in a Glioblastoma Xenograft Model. <i>Molecular Imaging and Biology</i> , 2019, 21, 705-712.	1.3	8
18	Ultra-High Dose Rate (FLASH) Radiotherapy: Silver Bullet or Fool's Gold?. <i>Frontiers in Oncology</i> , 2019, 9, 1563.	1.3	302

#	ARTICLE	IF	CITATIONS
19	Oxidative Phosphorylation as an Emerging Target in Cancer Therapy. <i>Clinical Cancer Research</i> , 2018, 24, 2482-2490.	3.2	687
20	The Future of Radiobiology. <i>Journal of the National Cancer Institute</i> , 2018, 110, 329-340.	3.0	76
21	4D-PET reconstruction using a spline-residue model with spatial and temporal roughness penalties. <i>Physics in Medicine and Biology</i> , 2018, 63, 095013.	1.6	4
22	Beyond PARP as a POL $\eta$ as an anticancer target. <i>Science</i> , 2018, 359, 1217-1218.	6.0	70
23	Whole tumor kinetics analysis of <sup>18</sup> F-fluoromisonidazole dynamic PET scans of non-small cell lung cancer patients, and correlations with perfusion CT blood flow. <i>EJNMMI Research</i> , 2018, 8, 73.	1.1	4
24	T-LAK cell-originated protein kinase (TOPK): an emerging target for cancer-specific therapeutics. <i>Cell Death and Disease</i> , 2018, 9, 1089.	2.7	60
25	CDK1 inhibition sensitizes normal cells to DNA damage in a cell cycle dependent manner. <i>Cell Cycle</i> , 2018, 17, 1513-1523.	1.3	59
26	Nucleoporin 54 contributes to homologous recombination repair and post-replicative DNA integrity. <i>Nucleic Acids Research</i> , 2018, 46, 7731-7746.	6.5	11
27	Depletion of signal recognition particle 72kDa increases radiosensitivity. <i>Cancer Biology and Therapy</i> , 2017, 18, 425-432.	1.5	8
28	IGF-1R associates with adverse outcomes after radical radiotherapy for prostate cancer. <i>British Journal of Cancer</i> , 2017, 117, 1600-1606.	2.9	35
29	<sup>18</sup> F-fluoromisonidazole uptake in advanced stage non-small cell lung cancer: A voxel-by-voxel PET kinetics study. <i>Medical Physics</i> , 2017, 44, 4665-4676.	1.6	16
30	TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy. <i>British Journal of Cancer</i> , 2017, 117, 503-512.	2.9	20
31	A new roadmap to improve translation of imaging biomarkers. <i>British Journal of Cancer</i> , 2016, 115, 1443-1444.	2.9	1
32	Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials. <i>Clinical Cancer Research</i> , 2016, 22, 3138-3147.	3.2	68
33	A role for human homologous recombination factors in suppressing microhomology-mediated end joining. <i>Nucleic Acids Research</i> , 2016, 44, 5743-5757.	6.5	83
34	Dose and Fractionation in Radiation Therapy of Curative Intent for Non-Small Cell Lung Cancer: Meta-Analysis of Randomized Trials. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 736-747.	0.4	78
35	The anti-malarial atovaquone increases radiosensitivity by alleviating tumour hypoxia. <i>Nature Communications</i> , 2016, 7, 12308.	5.8	173
36	Personalized Radiation Oncology: Epidermal Growth Factor Receptor and Other Receptor Tyrosine Kinase Inhibitors. <i>Recent Results in Cancer Research</i> , 2016, 198, 107-122.	1.8	12

#	ARTICLE	IF	CITATIONS
37	<sup>18</sup> F-Misonidazole PET-CT scan detection of occult bone metastasis. <i>Thorax</i> , 2016, 71, 97-97.	2.7	3
38	Drug radiotherapy combinations: Review of previous failures and reasons for future optimism. <i>Cancer Treatment Reviews</i> , 2015, 41, 105-113.	3.4	78
39	Identification of vitamin B1 metabolism as a tumor-specific radiosensitizing pathway using a high-throughput colony formation screen. <i>Oncotarget</i> , 2015, 6, 5978-5989.	0.8	33
40	NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivity. <i>Radiation Oncology</i> , 2012, 7, 48.	1.2	73
41	A Small Interfering RNA Screen of Genes Involved in DNA Repair Identifies Tumor-Specific Radiosensitization by POLQ Knockdown. <i>Cancer Research</i> , 2010, 70, 2984-2993.	0.4	116
42	Overexpression of <i>POLQ</i> Confers a Poor Prognosis in Early Breast Cancer Patients. <i>Oncotarget</i> , 2010, 1, 175-184.	0.8	100